Barclays raised the firm’s price target on Zoetis to $260 from $255 and keeps an Overweight rating on the shares. The company’s “mixed” Q4 gave something for the bears, but a solid revenue outlook for 2024 reaffirmed both Librela strength and animal health fundamentals, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ZTS:
